TPE-Nabs Combination Therapy for Severe COVID-19

Abstract

The pandemic spread of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires very urgently to identify effective therapies and prophylaxis. This appears perhaps even more imperative, after remdesivir, seemingly the most promising antiviral drug with very potent in vitro activity against SARS-CoV-2, was tested in adults with severe COVID-19 in a randomized, double-blind, placebo-controlled, multi-centre trial with somewhat disappointing results [1] (quote): “In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.”